Insulet Corporation
General ticker "PODD" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $20.6B (TTM average)
Insulet Corporation follows the US Stock Market performance with the rate: 6.6%.
Estimated limits based on current volatility of 1.2%: low 200.77$, high 205.67$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 3900 as of 2024
- US accounted for 74.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Supply chain disruptions, Litigation risks, Operational and conduct risks, Regulatory and compliance
- Current price 14.9% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [239.31$, 363.79$]
- 2026-12-31 to 2027-12-31 estimated range: [239.24$, 365.28$]
Financial Metrics affecting the PODD estimates:
- Negative: with PPE of 57.9 at the end of fiscal year the price was high
- Positive: 7.68 < Operating profit margin, % of 17.50
- Positive: 42.60 < Shareholder equity ratio, % of 47.49 <= 64.25
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.19 > 6.12
- Positive: 0.07 < Operating cash flow per share per price, % of 2.80
- Negative: Industry earnings per price (median), % of -2.21 <= 0
- Positive: -4.45 < Investing cash flow per share per price, % of -1.10
- Negative: 0.01 < Interest expense per share per price, % of 0.39
Short-term PODD quotes
Relationship graph
Long-term PODD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,697.10MM | $2,071.60MM | $2,708.10MM |
| Operating Expenses | $1,477.10MM | $1,762.70MM | $2,234.30MM |
| Operating Income | $220.00MM | $308.90MM | $473.80MM |
| Non-Operating Income | $-5.40MM | $-8.70MM | $-134.30MM |
| Interest Expense | $36.20MM | $42.70MM | $79.70MM |
| R&D Expense | $205.00MM | $219.60MM | $301.10MM |
| Income(Loss) | $214.60MM | $300.20MM | $339.50MM |
| Taxes | $8.30MM | $-118.10MM | $92.40MM |
| Profit(Loss)* | $206.30MM | $418.30MM | $247.10MM |
| Stockholders Equity | $732.70MM | $1,211.60MM | $1,515.20MM |
| Inventory | $402.60MM | $430.40MM | $452.60MM |
| Assets | $2,588.20MM | $3,087.70MM | $3,190.40MM |
| Operating Cash Flow | $145.70MM | $430.30MM | $569.30MM |
| Capital expenditure | $75.60MM | $124.90MM | $191.60MM |
| Investing Cash Flow | $-119.40MM | $-146.20MM | $-222.70MM |
| Financing Cash Flow | $-13.60MM | $-28.10MM | $-595.30MM |
| Earnings Per Share** | $2.96 | $5.97 | $3.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.